Journal
CELL
Volume 171, Issue 4, Pages 849-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2017.10.005
Keywords
-
Categories
Funding
- NIH [R01CA105241, R01NS065237, R01HL135160]
- Endowment for Research in Human Biology, Vertex Pharmaceuticals
- Pfizer's Center for Therapeutic Innovation
- NIH fellowship [F31HL128127]
- NSFC [81272674]
- Natalie V. Zucker Award
- Sackler Dean's Fellow Award
- Sackler Families Collaborative Cancer Biology Award
Ask authors/readers for more resources
Angiogenin (ANG) is a secreted ribonuclease (RNase) with cell-type- and context-specific roles in growth, survival, and regeneration. Although these functions require receptor-mediated endocytosis and appropriate subcellular localization, the identity of the cell surface receptor remains undefined. Here, we show that plexin-B2 (PLXNB2) is the functional receptor for ANG in endothelial, cancer, neuronal, and normal hematopoietic and leukemic stem and progenitor cells. Mechanistically, PLXNB2 mediates intracellular RNA processing that contribute to cell growth, survival, and regenerative capabilities of ANG. Antibodies generated against the ANG-binding site on PLXNB2 restricts ANG activity in vitro and in vivo, resulting in inhibition of established xenograft tumors, ANG-induced neurogenesis and neuroprotection, levels of pro-self-renewal transcripts in hematopoietic and patient-derived leukemic stem and progenitor cells, and reduced progression of leukemia in vivo. PLXNB2 is therefore required for the physiological and pathological functions of ANG and has significant therapeutic potential in solid and hematopoietic cancers and neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available